L-97-1

L-97-1 is a **small molecule adenosine A1 receptor antagonist** developed as an investigational intravenous therapy primarily for the treatment of severe sepsis and acute lung injury. It has been shown in preclinical animal models (notably rat models of cecal ligation and puncture-induced sepsis and Yersinia pestis-induced pneumonic plague) to significantly improve survival, protect against acute renal injury, and reduce acute lung injury when administered in combination with broad-spectrum antibiotics. The drug acts by antagonizing the adenosine A1 receptor, thereby reducing deleterious inflammatory and thromboxane responses during severe infection[1][2][3][5].